| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
GROWTH, DIFFERENTIATION, AND APOPTOSIS
Division of Rheumatology and Immunology, Duke University Medical Center, and Medical Research Service, Durham Veterans Affairs Hospital, Durham, North Carolina
Submitted 12 December 2005 ; accepted in final form 17 July 2006
 |
ABSTRACT |
|---|
 TOP ABSTRACT MATERIALS AND METHODSRESULTSDISCUSSIONGRANTSREFERENCES |
|---|
necrosis; cytokines; inflammation
Although HMGB1 release occurs with both cell activation and cell death, the mechanisms for release are distinct (5, 6, 8, 13, 21, 32, 41, 43, 44, 48). Translocation during activation involves protein acetylation, with the change in charge reducing the interaction with chromatin, and translocation into the cytoplasm for uptake into vesicles. In this setting, HMGB1 secretion occurs from vesicles, with this process augmented by agents such as lysophatidylcholine (8, 21). With necrosis, the release process appears immediate, with HMGB1 separating from chromatin since its binding to DNA is weaker than that of histones (5, 6, 43, 44, 48). The permeability of the nuclear and cellular membranes with necrosis may allow a passive exit process.
In contrast to findings with necrotic cells, analysis of cells undergoing apoptosis has indicated that HMGB1 release does not occur during this process, even during late stages when cells may undergo secondary necrosis and could show breakdown in membrane permeability (43, 44). The failure of this release, which could explain why apoptotic death is noninflammatory (24, 33), contrasts with the release of other nuclear molecules during apoptosis (4, 23, 31). Thus recent studies in our laboratory have focused on DNA release during cell death. With the use of Jurkat cells as a model, our findings indicate that apoptotic, but not necrotic, cells release DNA in a time-dependent manner (14, 15). This release has been observed with all inducers of apoptosis tested. Furthermore, since this release can be blocked by caspase inhibitors, a relationship to apoptosis can be established. Since the binding of HMGB1 to chromatin can be increased during apoptosis, the failure to show externalization of HMGB1 for this process is surprising.
Among explanations for the divergent findings on DNA and HMGB1 release, we considered the possibility that nuclear molecule release may differ among cell types, with inducing mechanism also impacting on release. In these studies, we have therefore investigated HMGB1 release from the Jurkat T cell line undergoing apoptosis. In results presented, we show that during the course of apoptosis of Jurkat cells treated with various agents, HMGB1 was released into the media as assessed by Western blotting. This release was blocked by an inhibitor of apoptosis. These results thus contrast with previous studies indicating that HMGB1 remains sequestered in the nucleus even as cells progress to late apoptosis and secondary necrosis (44). Together with studies on DNA, these findings indicate that a variety of nuclear molecules may exit the cell during apoptotic death and that nuclear molecule release may vary with cell type, inducing stimulus as well as a stage in the death process.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONGRANTSREFERENCES |
|---|
Induction of apoptosis or necrosis.
Apoptosis was induced by treating 10 x 106 cells in 4 ml of medium with 30 µg/ml etoposide, 10 µg/ml camptothecin, 5 µM staurosporine (STS), 70 µM cycloheximide (CHX), or 70 µM CHX and 2 ng/ml tumor necrosis factor (TNF)-
. To assess the effects of apoptosis, we first treated cells with a 30-min preincubation with 100 µM caspase inhibitor I [Z-Val-Ala-Asp(OMe)-CH2F (Z-VAD-fmk); Calbiochem, San Diego, CA] for Jurkat and Panc-1 cells or 50 µM Z-VAD-fmk for U937 cells. Cells were treated with inducers of apoptosis for the indicated times. In some experiments, HeLa cells were also treated with 200 ng/ml trichostatin A (TSA; Alexis Biochemicals, San Diego, CA) for 30 h. For induction of necrosis, cells were treated with heat to 56°C for 30 min or three cycles of freeze-thaw. Supernatants were collected from necrotic or apoptotic cells by centrifugation at 500 g for 5 min and stored at –80°C until used.
Detection of cell death. Cell death was detected by annexin V-fluorescein isothiocyanate (annexin V-FITC) and propidium iodide (PI) staining of necrotic and apoptotic cells. Cells were washed in PBS and resuspended in 100 µl of binding buffer containing 5 µl of annexin V-FITC (Molecular Probes, Carlsbad, CA) and 1 µg/ml PI and then incubated for 10 min at room temperature (RT) in the dark. Cells were analyzed using a FACScan (Becton Dickinson, San Jose, CA). Data were analyzed using CELLQuest software (Becton Dickinson).
Caspase-3 assay. Caspase-3 was assayed using a kit (Molecular Probes E12184 [GenBank] ). Briefly, supernatants of treated cells were added to caspase-3 substrate solution in a black 96-well microtiter plate (Costar; Corning, Corning, NY). Samples were incubated at RT in the dark for 30 min. Relative fluorescence units were determined using a TECAN GENios microplate reader with an excitation wavelength at 485 nm and an emission wavelength of 535 nm.
Western blotting for HMGB1 detection. Conditioned media from cells were centrifuged through Centricon (Millipore, Billerica, MA) 10-kDa filter devices for 1 h at 3,000 g. Supernatants were collected from the top reservoir of the filter device and spun through an Ultrafree-MC (Millipore) 100-kDa filter device for 15 min at 4,000 g. Equal volumes of elute were fractioned by SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Invitrogen Life Technologies). Membranes were probed with a 1:3,000 dilution of purified rabbit anti-HMGB1 (Pharmingen, San Jose, CA). Bound antibody was detected using a 1:1,000 dilution of goat anti-rabbit horseradish peroxidase-conjugated antibody (Pierce, Rockford, IL) and visualized by chemiluminescence (Supersignal West Femto maximum sensitivity substrate; Pierce) according to the manufacturer’s recommendations and viewed on a Fluorchem 8900 instrument (Alpha Innotech, San Leandro, CA).
Confocal microscopy and immunocytochemistry. Cells were induced to undergo apoptosis in LabTek II chambers (Nalgene Labware, Rochester, NY). Cells were fixed and permeabilized using the Cytofix/Cytoperm Plus with GolgiStop kit (Pharmingen) according to the manufacturer’s recommendations. In brief, cells were fixed and permeabilized for 20 min at 4°C. They were then washed three times with wash buffer and then incubated in 0.5 µg/ml anti-HMGB1 for 20 min at 4°C and washed. Next, 10 µg/ml goat anti-rabbit IgG Alexa Fluor 488 (Molecular Probes) were added for 20 min and cells were washed. Finally, cells were incubated with 1 µg/ml DRAQ5 (Alexis Biochemicals) for 10 min at RT and washed. Cells were visualized on a LSM510 confocal microscope (Zeiss, Oberkochen, Germany).
|
RESULTS |
|---|
|
TOPABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONGRANTSREFERENCES |
|---|
|
|
or the combination of CHX and TNF- with TSA for the indicated times; TSA was included in these experiments in view of data showing that inhibition of histone deacetylase by TSA causes biochemical changes that allow the release of HMGB1 from apoptotic cells. Detection of apoptosis was measured by the staining of cells with annexin-V-FITC and PI (Fig. 3A) or by caspase-3 activity (Fig. 3B).
|
or the combination of these agents with TSA underwent apoptosis, whereas Z-VAD-fmk reduced the amount of apoptosis (Fig. 3, A and B). To determine whether HMGB1 was released into the supernatants of cells under these conditions, supernatants were concentrated and analyzed on SDS-PAGE gel. As indicated in Fig. 3C, HeLa cells treated with CHX and TNF- released HMGB1 into the supernatants. HeLa cells treated with CHX, TNF-, and TSA also released HMGB1 into the supernatants. In the presence of the caspase inhibitor Z-VAD-fmk, HMGB1 was not detected in the supernatants (Fig. 3C). In contrast to previous studies (44), these results indicate that during the process of apoptosis, HeLa cells release HMGB1 into the supernatant and that protein acetylation is not required for this process.
Additional experiments were therefore performed to assess potential differences between Jurkat and HeLa cells in this response. Since CHX and TNF- induce apoptosis and Jurkat cells undergoing apoptosis release HMGB1, we measured HMGB1 release by Jurkat cells treated with CHX and TNF-. The presence of apoptosis was confirmed by annexin-V-FITC and PI staining (data not shown). As shown in Fig. 3D, Jurkat cells, when treated with CHX alone or in combination with TNF-, released HMGB1 into the supernatants at 24 and 30 h of incubation. These results confirm studies with HeLa cells and indicate that the combination of CHX and TNF- can induce apoptosis and lead to HMGB1 release.
Release of HMGB1 by apoptotic Panc-1 and U937 cells. To investigate whether cell lines other than Jurkat cells release HMGB1 during apoptosis, Panc-1 and U937 cells were induced to undergo apoptosis with STS or etoposide and supernatants were probed for HMGB1. As shown in Fig. 4, U937 cells (A) and Panc-1 cells (B) both released HMGB1 into the supernatants when treated with STS or etoposide at 4 and 30 h. Similarly to results with Jurkat cells, Z-VAD-fmk reduced the release of HMGB1 in cells treated with etoposide or STS. These results indicate that HMGB1 release is not confined to apoptotic Jurkat cells.
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONGRANTSREFERENCES |
|---|
These findings differ from prior studies indicating that necrosis, but not apoptosis, leads to HMGB1 release (44). In these experiments, even during late apoptosis (i.e., secondary necrosis) HMGB1 release did not occur, perhaps reflecting molecular changes that anchored this protein to chromatin. Given the cytokine activities of HMGB1 (1–3, 5, 32, 47), this result could explain the differing immunologic properties of apoptotic and necrotic cells, with apoptotic cells considered anti-inflammatory and necrotic cells considered proinflammatory. The validity of this distinction, however, is dependent on the robustness of the results and the influence of variables such as the cell type tested, the inducing stimulus for apoptosis, and the physical or chemical treatment causing necrosis.
Previous studies on this topic used HeLa cells and fibroblasts as models, inducing apoptosis by treatment with TNF- and CHX and necrosis with metabolic inhibitors (43, 44). In contrast, we used Jurkat cells treated with pharmacological inducers of apoptosis and showed that these cells, like cells induced to undergo necrosis by heat treatment or freeze-thawing (Fig. 2B), release HMGB1 over time in culture. This release was observed with all inducers of apoptosis. To assure validity of this result, we assessed HeLa cells using CHX and TNF- to induce apoptosis and showed that under these conditions, HMGB1 was released; this result differs from previous studies of Scaffidi et al. (44), which indicated that even after prolonged incubation following induction of apoptosis, HMGB1 remained intracellular, with inhibition of protein acetylation necessary to cause its release. Furthermore, in our studies, Jurkat cells treated with CHX and TNF-, U937 cells treated with STS or etoposide, and Panc-1 cells treated with STS or etoposide all released HMGB1.
Together, our results indicate that HMGB1 release is a feature of apoptosis of at least some cell types and likely occurs during late apoptosis, a stage that can be considered as secondary necrosis. In this stage, cells may display permeability changes, since they will allow entry of PI on one hand, as well as exit of molecules such as DNA, caspase-3, lactate dehydrogenase (LDH), cytochrome c, and cytokeratin fragments on the other (4, 16, 22, 23, 26–28, 30, 31, 42, 45). According to this model, HMGB1 would reflect nonspecific leakage of nuclear contents that occurs late in apoptosis despite cell shrinkage and chromatin condensation. In this regard, there is evidence that the lamin in the nuclear membrane is cleaved during apoptosis, eliminating the permeability barrier and allowing dispersal of molecules such as DNA or RNA into the cytoplasm and then the extracellular milieu (7, 19, 20, 35, 39).
In previous studies, the mobility of a fusion protein of HMGB1 and green fluorescent protein was assessed as fluorescence loss of photobleaching (FLIP analysis) in HeLa cells to determine intranuclear diffusion during apoptosis (44). These experiments indicated that during apoptosis, HMGB1 has very limited mobility, with a diffusion coefficient significantly lower than that of the nuclear proteins HMGN1, HMGN2, or NF1. These findings suggest that molecular changes in the nucleus occurring during apoptosis cause tight binding of HMGB1 to the chromatin. Our results suggest either that at least some HMGB1 remains sufficiently mobile in the cell to allow its exit as apoptosis proceeds or that tight binding diminishes over time. The more mobile HMGB1 protein could reside in the cytoplasm, since HMGB1 in some cells may have cytoplasmic as well as nuclear localization (10, 25, 34, 36). In this regard, in certain cell types, HMGB1 may remain intracellular even during necrosis. Thus, in polymorphonuclear cells, HMGB1 is found in cytoplasmic vesicles, where it is tightly bound in an insoluble form; in these cells, necrosis is insufficient to release HMGB1 (43).
Although permeability changes could lead to the exit of nuclear and cytoplasmic molecules during apoptosis, the shifts of these molecules may not simply be a passive release. Thus, in HBL100 breast cancer cells treated with paclitaxel to induce apoptosis, the release of CK18 cytokeratin fragment occurs significantly earlier than the release of LDH (45). Similarly, in Jurkat cells, the release of glutathione appears to result from transport as opposed to diffusion (17). Thus the release of molecules during apoptosis may be a selective process and results from more than one mechanism.
To the extent that permeability changes allow leakage of nuclear contents during apoptosis, the release of HMGB1 during late apoptosis may resemble that occurring during necrosis, with these processes distinct from that occurring during cell activation. Cell activation involves active secretion of HMGB1 that has been acetylated and translocated into vesicles (21). Although apoptosis involves extensive proteolytic cleavage and protein translocation, studies thus far do not show either cleavage of HMGB1 or movement of this protein into blebs (11, 12). These issues are under investigation, however, and we cannot exclude the possibility that at least some of the HMGB1 release occurs in the form of blebs or microparticles released from the cell membrane as the apoptotic cells breaks down.
Although this mechanism can explain the release of HMGB1 during apoptosis, it does not explain the differences in the behavior of DNA and HMGB1 during necrosis. Thus our findings indicate that DNA release does not occur in cultures of Jurkat cells treated with heat to induce necrosis (14, 15). Nevertheless, we observed release of HMGB1 release under these circumstances (Fig. 2B). The basis for this difference is not clear, although it appears likely that the agents we used to induce necrosis can cause either cross-linking or denaturation of chromatin in such a form that exit of DNA from the cell is not possible. We have used freeze-thawing to induce necrosis, but in our experience, cells treated this way are severely fragmented and become permeable. The most appropriate system for inducing necrosis in a "physiological" way is speculative. This issue is also relevant to the quantitative assessment of HMGB1 during different forms of death, because release with freeze-thawing may be much more extensive than that occurring with chemical agents.
Previous studies on HMGB1 release during death have suggested that the failure of apoptotic cells to release this protein could contribute to an anti-inflammatory state (7). To the extent that HMGB1 release promotes inflammation, our findings could suggest that the anti-inflammatory nature of apoptotic cells is transient and that as cells transit to late apoptosis, HMGB1 can exit cells and stimulate inflammation. Indeed, in preliminary experiments, we have shown that concentrated supernatants of Jurkat cells induced to undergo apoptosis by treatment with UV-B light can stimulate the production of nitric oxide and IL-12 by RAW 264.7 cells primed with interferon-
; under these conditions, supernatants of necrotic cells were also active (Bell CW and Pisetsky DS, unpublished observations). Since these supernatants of apoptotic cells undoubtedly have many components, it is premature to conclude that HMGB1 is the active moiety. In this regard, HMGB1 may act in concert with other released molecules, including DNA, which is present in these supernatants. The interaction of HMGB1 with DNA could create a complex that is immunologically active, since HMGB1 promotes DNA uptake into cells, mimicking the immune stimulatory activity of other DNA with transfection agents (9, 29). These issues are under investigation.
Studies on systemic lupus erythematosus (SLE) have suggested that a failure to clear apoptotic cells can underlie the generation of autoimmune responses (37, 40), with these cells being effective immunogens by virtue of their display of nuclear molecules in blebs (11, 12). Our results further suggest that HMGB1 could contribute to this process, since it is a highly effective adjuvant, with both generation of these blebs as well as the release of HMGB1 occurring most readily in the absence of effective clearance as may occur in SLE. Indeed, skin lesions of patients with SLE have an increased levels of extracellular HMGB1; since this lesion is associated with increased apoptosis, the source of this material could be apoptotic cells as well as inflammatory cells present (38). Although the origin of extracellular HMGB1 in disease settings must be the subject of future investigation, the current studies suggest a broader perspective on the release of this protein and recognition of its appearance during apoptosis as well as necrosis.
|
GRANTS |
|---|
|
TOPABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONGRANTSREFERENCES |
|---|
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
|
REFERENCES |
|---|
|
TOPABSTRACTMATERIALS AND METHODSRESULTSDISCUSSIONGRANTSREFERENCES |
|---|
2. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, and Tracey KJ. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192: 565–570, 2000.
3. Andersson U, Erlandsson-Harris H, Yang H, and Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 72: 1084–1091, 2002.
4. Anker P and Stroun M. Progress in the knowledge of circulating nucleic acids: plasma RNA is particle-associated. Can it become a general detection marker for a cancer blood test? Clin Chem 48: 1210–1211, 2002.
5. Bianchi ME. Significant (re)location: how to use chromatin and/or abundant proteins as messages of life and death. Trends Cell Biol 4: 287–293, 2004.
6. Bianchi ME and Manfredi A. Chromatin and cell death. Biochim Biophys Acta 1677: 181–186, 2004.[Medline]
7. Biggiogera M, Bottone MG, and Pellicciari C. Nuclear RNA is extruded from apoptotic cells. J Histochem Cytochem 46: 999–1005, 1997.
8. Bonaldi T, Talamo F, Scaffidi P, Perrera D, Porto A, Bachi A, Rubartelli A, Agresti A, and Bianchi ME. Monocyte cells hyperactylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22: 5551–5560, 2003.[CrossRef][Web of Science][Medline]
9. Bottger M, Vogel F, Kiessling M, Grade U, and Strauss M. Condensation of vector DNA by the chromosomal protein HMG1 results in efficient transfection. Biochim Biophys Acta 950: 221–228, 1988.[Medline]
10. Bustin M and Neihart NK. Antibodies against chromosomal HMG proteins stain the cytoplasm of mammalian cells. Cell 16: 181–189, 1979.[CrossRef][Web of Science][Medline]
11. Casciola-Rosen LA, Anhalt G, and Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179: 1317–1330, 1994.
12. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, and Rosen A. Cleavage of granzyme B is strongly predictive of autoantigen status: implications for initiation for initiation of autoimmunity. J Exp Med 190: 815–825, 1999.
13. Chen G, Li J, Ochani M, Rendon-Mitchell B, Qiang X, Susaria S, Ulloa L, Yang H, Fan S, Goyert SM, Wang P, Tracey KJ, Sama AE, and Wang H. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol 76: 1–8, 2004.
14. Choi JJ, Reich CF, and Pisetsky DS. Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro. Scand J Immunol 60: 159–166, 2004.[CrossRef][Web of Science][Medline]
15. Choi JJ, Reich CF, and Pisetsky DS. The role of macrophage in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 115: 55–62, 2005.[CrossRef][Web of Science][Medline]
16. Decker T and Lohmann-Matthes MC. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115: 61–69, 1988.[CrossRef][Web of Science][Medline]
17. Dobbelsteen DJ van den, Nobe SI, Schlegel J, Cotgreave IA, Orrenius S, and Slater AFG. Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/APO-1 antibody. J Biol Chem 271: 15420–15427, 1996.
18. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, and Rovere-Querini P. HMGB1: guiding immunity from within. Trends Immunol 26: 381–387, 2005.[CrossRef][Web of Science][Medline]
19. Earnshaw WC. Nuclear changes in apoptosis. Curr Opin Cell Biol 7: 337–343, 1995.[CrossRef][Web of Science][Medline]
20. Faleiro L and Lavebnik Y. Caspases disrupt the nuclear-cytoplasmic barrier. J Cell Biol 151: 951–959, 2000.
21. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, and Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3: 995–1001, 2002.[CrossRef][Web of Science][Medline]
22. Harter L, Kell M, Hentze H, Leist M, and Ertel W. Caspase-3 activity is present in cerebrospinal fluid from patients with traumatic brain injury. J Neuroimmunol 121: 76–78, 2001.[CrossRef][Web of Science][Medline]
23. Hasselmann DO, Rappl G, Tilgen W, and Reinhold U. Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 47: 1488–1489, 2001.
24. Huynh MLN, Fadok VA, and Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promote TGF-
secretion and the resolution of inflammation. J Clin Invest 109: 41–50, 2002.[CrossRef][Web of Science][Medline]
25. Isackson PJ, Bidney DL, Reeck GR, Neihart NK, and Bustin M. High mobility group chromosomal proteins isolated from nuclei and cytosol of cultured hepatoma cells are similar. Biochemistry 19: 4466–4471, 1980.[CrossRef][Medline]
26. Jiang N, Reich CF III, and Pisetsky DS. Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells. Blood 102: 2243–2250, 2003.
27. Jiang N, Reich CF III, Monestier M, and Pisetsky DS. The expression of plasma nucleosomes in mice undergoing in vivo apoptosis. Clin Immunol 106: 139–147, 2003.[CrossRef][Web of Science][Medline]
28. Jiang N and Pisetsky DS. The effect of dexamethasone on the generation of plasma DNA from dead and dying cells. Am J Pathol 164: 1751–1759, 2004.
29. Jiang W, Reich CF III, and Pisetsky DS. Mechanisms of activation of the RAW264.7 macrophage cell line by transfected mammalian DNA. Cell Immunol 229: 31–40, 2004.[CrossRef][Web of Science][Medline]
30. Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, and Syrjanen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res 11: 1127–1131, 1994.[CrossRef][Web of Science][Medline]
31. Li CN, Hsu HL, Wu TL, Tsao KC, Sun CF, and Wu JT. Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J Clin Lab Anal 17: 103–107, 2003.[CrossRef][Web of Science][Medline]
32. Lotze MT and Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. EMBO Rep 5: 331–342, 2005.
33. McDonald PP, Fadok VA, Bratton D, and Henson PM. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF- in macrophages that have ingested apoptotic cells. J Immunol 163: 6164–6172, 1999.
34. Muller S, Ronfani L, and Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 255: 332–343, 2004.[CrossRef][Web of Science][Medline]
35. Neamati N, Fernandez A, Wright S, Kiefer J, and McConkey DJ. Degradation of lamin B1 precedes oligonucleosome DNA fragmentation in apoptotic thymocytes and isolated thymocyte nuclei. J Immunol 154: 3788–3795, 1995.[Abstract]
36. Parkkinen J, Raulo E, Merenmies J, Nolo R, Kajander O, Baumann M, and Rauvala H. Amphoterin, the 30 kDa protein in a family of HMG1-type polypeptides. J Biol Chem 268: 19726–19738, 1993.
37. Pisetsky DS. DNA as a marker of cell death in systemic lupus erythematosus. Rheum Dis Clin North Am 30: 575–587, 2004.[CrossRef][Web of Science][Medline]
38. Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M, and Nyberg F. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 52: 3639–3645, 2005.[CrossRef][Web of Science][Medline]
39. Rao L, Perez D, and White E. Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol 135: 1441–1445, 1996.
40. Ren Y and Savill J. Apoptosis: the importance of being eaten. Cell Death Differ 5: 563–568, 1998.[CrossRef][Web of Science][Medline]
41. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, Susaria S, Czura C, Mitchell RA, Chen G, Sama SA, Tracey KJ, and Wang H. IFN- induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 170: 3890–3897, 2003.
42. Renz A, Berdel WE, Kreuter M, Belka C, Schulze-Osthoff K, and Los M. Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood 98: 1542–1548, 2001.
43. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalnotti F, Giazzon M, Dumitiriu IE, Muller S, Iannacone M, Traversari C, Bianchi M, and Manfredi AA. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5: 825–830, 2004.[CrossRef][Web of Science][Medline]
44. Scaffidi P, Misteli T, and Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191–195, 2002.[CrossRef][Medline]
45. Ueno T, Toi M, Biven K, Bando H, Ogawa T, and Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39: 769–774, 2003.[CrossRef][Web of Science][Medline]
46. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Yang H, Ivanova S, Borovikova L, Manogure LR, Faist E, Abraham E, Andersson U, Molina PR, Abumrad NN, Sama A, and Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248–251, 1999.
47. Yang H, Wang H, Czura CJ, and Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol 78: 1–8, 2005.
48. Zeh HJ and Lotze MT. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 28: 1–9, 2005.[Medline]
This article has been cited by other articles:
|
|
 |
|
  L. Campana, L. Bosurgi, M. E. Bianchi, A. A. Manfredi, and P. Rovere-Querini Requirement of HMGB1 for stromal cell-derived factor-1/CXCL12-dependent migration of macrophages and dendritic cells J. Leukoc. Biol., September 1, 2009; 86(3): 609 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Bianchi HMGB1 loves company J. Leukoc. Biol., September 1, 2009; 86(3): 573 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Urbonaviciute, B. G. Furnrohr, S. Meister, L. Munoz, P. Heyder, F. De Marchis, M. E. Bianchi, C. Kirschning, H. Wagner, A. A. Manfredi, et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE J. Exp. Med., December 22, 2008; 205(13): 3007 - 3018. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Aneja, A. Tsung, H. Sjodin, J. V. Gefter, R. L. Delude, T. R. Billiar, and M. P. Fink Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance J. Leukoc. Biol., November 1, 2008; 84(5): 1326 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Rowe, P. L. Jackson, G. Liu, M. Hardison, A. Livraghi, G. M. Solomon, D. B. McQuaid, B. D. Noerager, A. Gaggar, J. P. Clancy, et al. Potential Role of High-Mobility Group Box 1 in Cystic Fibrosis Airway Disease Am. J. Respir. Crit. Care Med., October 15, 2008; 178(8): 822 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Han, J. Zhong, W. Wei, Y. Wang, Y. Huang, P. Yang, S. Purohit, Z. Dong, M.-H. Wang, J.-X. She, et al. Extracellular High-Mobility Group Box 1 Acts as an Innate Immune Mediator to Enhance Autoimmune Progression and Diabetes Onset in NOD Mice Diabetes, August 1, 2008; 57(8): 2118 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Mares, S. S. Ojeda, E. G. Morris, Q. Li, and J. M. Teale Initial Delay in the Immune Response to Francisella tularensis Is Followed by Hypercytokinemia Characteristic of Severe Sepsis and Correlating with Upregulation and Release of Damage-Associated Molecular Patterns Infect. Immun., July 1, 2008; 76(7): 3001 - 3010. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kappes, J. Fahrer, M. S. Khodadoust, A. Tabbert, C. Strasser, N. Mor-Vaknin, M. Moreno-Villanueva, A. Burkle, D. M. Markovitz, and E. Ferrando-May DEK Is a Poly(ADP-Ribose) Acceptor in Apoptosis and Mediates Resistance to Genotoxic Stress Mol. Cell. Biol., May 15, 2008; 28(10): 3245 - 3257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Muller, J Dieker, A Tincani, and P. Meroni Pathogenic anti-nucleosome antibodies Lupus, May 1, 2008; 17(5): 431 - 436. [Abstract] [PDF]
|
|
|
|
 |
|
 W Jiang and D S Pisetsky Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus Ann Rheum Dis, May 1, 2008; 67(5): 727 - 728. [Full Text] [PDF]
|
|
|
|
|
|
J. H. H. Williams and H. E. Ireland Sensing danger--Hsp72 and HMGB1 as candidate signals J. Leukoc. Biol., March 1, 2008; 83(3): 489 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Zetterstrom, W. Jiang, H. Wahamaa, T. Ostberg, A.-C. Aveberger, H. Schierbeck, M. T. Lotze, U. Andersson, D. S. Pisetsky, and H. Erlandsson Harris Pivotal Advance: Inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate J. Leukoc. Biol., January 1, 2008; 83(1): 31 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. M. Maree, M. Komba, D. T. Finegood, and L. Edelstein-Keshet A quantitative comparison of rates of phagocytosis and digestion of apoptotic cells by macrophages from normal (BALB/c) and diabetes-prone (NOD) mice J Appl Physiol, January 1, 2008; 104(1): 157 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Barkauskaite, M. Ek, K. Popovic, H.E. Harris, M. Wahren-Herlenius, and F. Nyberg Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus Lupus, October 1, 2007; 16(10): 794 - 802. [Abstract] [PDF]
|
|
|
|
 |
|
 D. S. Pisetsky The Role of Nuclear Macromolecules in Innate Immunity Proceedings of the ATS, July 1, 2007; 4(3): 258 - 262. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
